Answers are grounded in this paper and cite their sources.
The incidence of immune-mediated diseases is increasing worldwide. Reliable immune markers for monitoring disease progression and also the effect of therapeutic interventions are urgently needed in order to investigate preventive or therapeutic measures effectively. At a recent workshop held on 5 December 1998 in Copenhagen, the state of research on surrogate markers in Type 1 diabetes was discussed and compared with the experience in multiple sclerosis, inflammatory bowel disease and transplantation.
No takes yet. Share an insight, caveat, or question.
Schloot et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: